Literature DB >> 2176518

Effect of erythropoietin on parameters of sympathetic nervous activity in patients undergoing chronic haemodialysis.

E Fritschka1, H H Neumayer, S Seddighi, H M Thiede, A Distler, T Philipp.   

Abstract

The effect of erythropoietin (rHu-EPO) on blood pressure and on parameters of sympathetic nervous activity of patients undergoing chronic haemodialysis treatment was evaluated in a controlled and randomized 6-months study. Both groups did not differ significantly at the onset of the study in terms of dialysis protocol, haematological parameters, blood chemistry, weight, blood pressure and parameters of sympathetic nervous activity. Haemoglobin increased from 7.0 +/- 0.3 g dl-1 to 10.0 +/- 0.3 g dl-1 by 6 months on rHu-EPO (n = 11) and remained constant in the control group (n = 11). After 6 months diastolic blood pressure was higher in the treatment group compared with the control group as well as compared with pretreatment values, whereas reactivity to exogenous noradrenaline and platelet alpha 2-adrenoceptor densities ([3H]-yohimbine- and [3H]-UK 14,304-binding sites) were lower. Plasma noradrenaline concentration increased during rHu-EPO compared with pretreatment values, while dry weights were unchanged during the study. The results demonstrate alterations of some parameters of sympathetic nervous activity during rHu-EPO-therapy which were absent in the control group.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2176518      PMCID: PMC1368115          DOI: 10.1111/j.1365-2125.1990.tb05485.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

Authors:  J W Eschbach; J C Egrie; M R Downing; J K Browne; J W Adamson
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

2.  Agonist binding at alpha 2-adrenoceptors of human platelets using 3H-UK-14,304: regulation by Gpp(NH)p and cations.

Authors:  J Schloos; A Wellstein; D Palm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

Review 3.  Recombinant human erythropoietin: implications for nephrology.

Authors:  J W Eschbach; J W Adamson
Journal:  Am J Kidney Dis       Date:  1988-03       Impact factor: 8.860

4.  Sympathetic nervous system and blood-pressure control in essential hypertension.

Authors:  T Philipp; A Distler; U Cordes
Journal:  Lancet       Date:  1978-11-04       Impact factor: 79.321

Review 5.  Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy.

Authors:  A E Raine
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

  5 in total
  2 in total

1.  [Disordered alpha 2-adrenoreceptor function in hemodialysis patients with renal anemia--a possible cause of increased blood pressure in relation to recombinant human erythropoietin?].

Authors:  R Müller; H M Steffen; R Brunner; M Pollok; C A Baldamus; W Kaufmann
Journal:  Klin Wochenschr       Date:  1991-10-18

Review 2.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.